Advaxis (ADXS) 10-Q2019 Q3 Quarterly report

Filed: 9 Sep 19, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accredited, aresubject, bid, cashlessly, certainstock, consecutive, cure, delist, delisted, delisting, Elanco, fusion, holder, home, IDMC, IST, merger, monetization, monitor, Monitoring, monthly, mortgage, nominal, ourability, penny, personalizedLm, proprietarytLLO, publicly, redirecting, registered, residence, shift, spouse, suggested, unblind, underwent, worth

Removed: accelerate, adequate, adjuvant, administered, Agency, CCRT, chemoradiation, compare, concurrent, consolidated, curative, ESPP, establish, examining, excellence, face, goal, HRLACC, investigation, lead, persistent, placebo, PreventCervical, protocol, radiotherapy, reached, recurrence, reimbursed, setting, SPA, submitted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ADXS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION-PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

The undersigned as Chief Financial Officer of Advaxis, Inc. (the “Company”), does hereby certify that the foregoing Quarterly Report on Form 10-Q of the Company for the quarter ended July 31, 2019:

	(1)	Fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	Fairly presents, in all material respects, the financial condition and result of operations of the Company.

September 9, 2019

/s/ Molly Henderson
Molly Henderson
Executive Vice President, Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.